Case C-353/08: Order of the Court (Seventh Chamber) of 9 November 2009 (reference for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio — Italy) — A. Menarini — Industrie Farmaceutiche Riunite Srl, FIRMA Srl, Laboratori Guidotti SpA, Menarini International Operations Luxembourg SA, Istituto Lusofarmaco d'Italia SpA, Malesi Istituto Farmacobiologico SpA v Ministero della Salute, Agenzia Italiana del Farmaco (AIFA) (First subparagraph of Article 104(3) of the Rules of Procedure — Directive 89/105/EEC — Transparency of measures regulating the prices of medicinal products for human use — Article 4(1) — Price freeze — Price reductions)
Date: 2009-11-09
Institutions: Court of Justice
Subjects: interpretation of the law, medicinal product, pharmaceutical industry, price increase








C_2010051EN.01001302.xml










27.2.2010   


EN


Official Journal of the European Union


C 51/13





Order of the Court (Seventh Chamber) of 9 November 2009 (reference for a preliminary ruling from the Tribunale Amministrativo Regionale del Lazio — Italy) — A. Menarini — Industrie Farmaceutiche Riunite Srl, FIRMA Srl, Laboratori Guidotti SpA, Menarini International Operations Luxembourg SA, Istituto Lusofarmaco d'Italia SpA, Malesi Istituto Farmacobiologico SpA v Ministero della Salute, Agenzia Italiana del Farmaco (AIFA)
(Case C-353/08) (1)

(First subparagraph of Article 104(3) of the Rules of Procedure - Directive 89/105/EEC - Transparency of measures regulating the prices of medicinal products for human use - Article 4(1) - Price freeze - Price reductions)
2010/C 51/21
Language of the case: Italian

Referring court

Tribunale Amministrativo Regionale del Lazio

Parties to the main proceedings


Applicants: A. Menarini — Industrie Farmaceutiche Riunite Srl, FIRMA Srl, Laboratori Guidotti SpA, Menarini International Operations Luxembourg SA, Istituto Lusofarmaco d'Italia SpA, Malesi Istituto Farmacobiologico SpA

Defendants: Ministero della Salute, Agenzia Italiana del Farmaco (AIFA)

Intervening party: Bracco SpA

Re:

Reference for a preliminary ruling — Tribunale Amministrativo Regionale del Lazio — Interpretation of Article 4(1) and (2) of Council Directive 89/15/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems (OJ 1989 L 40, p. 8) — Medicinal products covered by a price freeze — Procedures to be followed in the event of any decrease in prices

Operative part







1.


Article 4(1) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that, provided that the requirements laid down in that provision are respected, the competent authorities of a Member State may adopt general measures consisting of the reduction in the prices of all medicinal products or certain categories of medicinal products, even if the adoption of those measures is not preceded by a freezing of those prices.










2.


Article 4(1) of Directive 89/105 must be interpreted as meaning that, provided that the requirements laid down in that provision are respected, the adoption of measures to reduce the prices of all medicinal products or certain categories of medicinal products is possible several times per year and for many years.










3.


Article 4(1) of Directive 89/105 must be interpreted as not precluding the adoption of measures seeking to control the prices of all medicinal products or certain categories of medicinal products on the basis of expenditure predictions, provided that the requirements laid down in that provision are respected and that those predictions are based on objective and verifiable information.










4.


Article 4(1) of Directive 89/105 must be interpreted as meaning that it is the task of the Member States to determine, in compliance with the objective of transparency pursued by that directive and the requirements laid down in that provision, the criteria in accordance with which the macroeconomic conditions laid down in that provision are to be verified, and that that criteria may consist of pharmaceutical expenditure alone, of total health expenditure or other types of expenditure.






(1)  OJ C 313, 6.12.2008.